By Fineline Cube 
Insilico Medicine (HKG: 3696) and Hisun Pharmaceutical (SHA: 600267) announced the nomination of a Preclinical Candidate (PCC) for their collaborative project just eight months after signing their strategic partnership, showcasing the efficiency of Insilico’s Pharma.AI platform in accelerating early‑stage drug discovery.
Partnership Milestone
| Item | Detail |
|---|---|
| Companies | Insilico Medicine (3696.HK), Hisun Pharmaceutical (600267.SH) |
| Agreement | Strategic partnership signed April 2025 |
| Technology | Insilico’s proprietary Pharma.AI platform |
| Achievement | PCC nomination |
| Timeline | 8 months from partnership initiation |
| Focus | Co‑development of AI‑driven innovative drugs for selected therapeutic targets |
Strategic Significance
Accelerated R&D Timeline:
- Traditional drug discovery: 12‑18 months to PCC nomination
- AI‑driven approach: 8 months demonstrates 30‑50% time savings
- Cost Efficiency: Estimated 40% reduction in early‑stage R&D expenses
Portfolio Impact: The PCC nomination marks the first tangible output from the partnership, validating Insilico’s generative AI capabilities and Hisun’s biopharmaceutical development expertise.
Technology Profile: Pharma.AI Platform
- Capabilities: Chemistry42 for de novo molecule design, PandaOmics for target identification, InClinico for trial prediction
- Efficiency: Completed target validation, hit identification, lead optimization, and preclinical studies in 8 months
- Differentiation: Integrates deep learning with biological data to predict efficacy and safety profiles early
Deal Structure & Market Context
Financial Terms: Undisclosed; typical AI‑driven partnerships involve milestone‑based payments and royalty sharing.
Market Opportunity: China’s AI‑enabled drug discovery market is projected to reach ¥15 billion by 2028, growing at a 35% CAGR, driven by demand for faster, more cost‑effective R&D.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the Insilico‑Hisun partnership’s development timeline, AI platform capabilities, and market potential. Actual results may differ due to clinical outcomes, competitive dynamics, and regulatory decisions.-Fineline Info & Tech